Holen Sie sich die Stockscreener-App
216.50
2.84%
-6.32
Vorhandelsmarkt:
217.48
0.98
+0.45%
Schlusskurs vom Vortag:
$222.82
Offen:
$221.66
24-Stunden-Volumen:
1.03M
Relative Volume:
0.73
Marktkapitalisierung:
$31.01B
Einnahmen:
$2.50B
Nettoeinkommen (Verlust:
$-226.32M
KGV:
-131.92
EPS:
-1.6412
Netto-Cashflow:
$71.51M
1W Leistung:
+2.19%
1M Leistung:
+11.46%
6M Leistung:
-7.13%
1J Leistung:
+31.04%
1-Tages-Spanne:
$215.51
$224.70
1-Wochen-Bereich:
$211.25
$227.90
52-Wochen-Spanne:
$131.81
$256.36
Natera Inc Stock (NTRA) Company Profile
Firmenname
Natera Inc
Sektor
Branche
Telefon
650-249-9090
Adresse
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
216.50 | 31.01B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
482.04 | 179.14B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
183.63 | 129.97B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
556.94 | 43.93B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
131.62 | 37.17B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
363.18 | 35.66B | 3.77B | 449.25M | 240.68M | 7.8556 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | William Blair | Outperform |
| 2026-01-07 | Eingeleitet | Citigroup | Buy |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-10-27 | Hochstufung | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-08 | Fortgesetzt | Craig Hallum | Buy |
| 2024-02-20 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-11-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Eingeleitet | Stephens | Overweight |
| 2022-03-08 | Eingeleitet | Goldman | Buy |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-09-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-09-17 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-05-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Eingeleitet | JP Morgan | Neutral |
| 2018-07-05 | Bestätigt | Piper Jaffray | Overweight |
| 2017-08-07 | Bestätigt | Morgan Stanley | Overweight |
| 2016-11-10 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-23 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-11 | Bestätigt | The Benchmark Company | Buy |
| 2016-04-19 | Eingeleitet | The Benchmark Company | Buy |
| 2015-09-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2015-08-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2015-07-27 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-07-27 | Eingeleitet | Wedbush | Neutral |
Alle ansehen
Natera Inc Aktie (NTRA) Neueste Nachrichten
Natera expands Austin operations with new sequencing facility - MSN
Natera director Marcus Boxer sells $2.39 million in stock - Investing.com UK
Natera director Marcus Boxer sells $2.39 million in stock By Investing.com - Investing.com Nigeria
[Form 4] Natera, Inc. Insider Trading Activity - Stock Titan
[Form 3] Natera, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Natera to launch enhanced Panorama NIPT for low fetal fractions - MSN
Have Natera Insiders Been Selling Stock? - simplywall.st
NTRA & Diakonos partner to use Signatera in refractory melanoma trial - MSN
NTRA & CytoDyn Partner to Advance ctDNA-Guided Development in mCRC - Yahoo Finance
Natera Pushes MRD And Panorama Into Treatment Guiding Roles - Yahoo Finance
Billionaire Stanley Druckenmiller Likes This Cancer Stock - Insider Monkey
How Investors May Respond To Natera (NTRA) Expanding Signatera MRD Reach Amid Insider Share Sale - simplywall.st
Natera, Inc. (NTRA) Stock Analysis: Insights into a High-Growth Diagnostics Leader with a 20% Upside Potential - DirectorsTalk Interviews
This Insider Has Just Sold Shares In Natera - Moomoo
Net income of Natera, Inc. – XETR:45E - TradingView
Assessing Natera (NTRA) Valuation After Strong Multi Year Returns And Recent Share Price Cooling - simplywall.st
5 Healthcare Stocks That the AI Crowd Is Overlooking - Barron's
Natera, Inc. Balance Sheet – XETR:45E - TradingView
Goldman Sachs Initiates Natera(NTRA.US) With Hold Rating, Announces Target Price $245 - Moomoo
Natera's EXPAND trial enrollment crosses 2,000 patient milestone - MSN
Insider Sell Alert: Steven Chapman Sells 41,124 Shares of Natera Inc (NTRA) - GuruFocus
Natera CEO Steven Chapman sells $9.09 million in company stock By Investing.com - Investing.com South Africa
Natera CEO Steven Chapman sells $9.09 million in company stock - Investing.com UK
Natera(NTRA.US) Officer Sells US$9.09 Million in Common Stock - Moomoo
Natera (NTRA) CEO Chapman sells 41,124 shares under 10b5-1 plan - Stock Titan
(NTRA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
[144] Natera, Inc. SEC Filing - Stock Titan
Natera Expands Board, Appoints Thomas Lynch as Director - TipRanks
Natera (NTRA) appoints independent director Thomas Lynch and expands board - Stock Titan
Natera executive chairman sells $1.64m in shares - Investing.com
NTRA Initiates Coverage On Goldman Sachs -- Rating Set to Neutra - GuruFocus
Natera, Inc. Earnings and Revenue – XETR:45E - TradingView
Goldman Sachs initiates Natera stock with Neutral rating, $245 target - Investing.com UK
Goldman Sachs initiates Natera stock with Neutral rating, $245 target By Investing.com - Investing.com Australia
Natera CytoDyn Signatera Pact Highlights Data Assets And Rich Valuation - simplywall.st
Natera partners with CytoDyn on cancer treatment research By Investing.com - Investing.com South Africa
Steven L. Chapman reports common‑share sales (NASDAQ: NTRA) - Stock Titan
CytoDyn (CYDY) Teams Up with Natera for Cancer Research Collaboration - GuruFocus
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer - CytoDyn Inc.
Natera Inc stock (US6323071042): insider sales and new oncology board appointments in focus - AD HOC NEWS
Natera, CytoDyn Partner in Colorectal Cancer Study - Contract Pharma
Natera partners with CytoDyn on cancer treatment research - Investing.com
Natera adds two oncology experts to board of directors - Investing.com UK
Insider Sell Alert: Solomon Moshkevich Sells 3,000 Shares of Nat - GuruFocus
Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors - BioSpace
Finanzdaten der Natera Inc-Aktie (NTRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.19%
1.52%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):